Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SS Innovations International ( (SSII) ) has provided an announcement.
On March 30, 2026, SS Innovations announced it had secured regulatory approvals for its SSi Mantra surgical robotic system for multiple indications in Colombia, Oman, Sri Lanka and Kenya, with approvals granted between November 2025 and January 2026. These authorizations add to a growing global footprint that already includes markets such as India, Ecuador, Indonesia, the Philippines, Ukraine and the United Arab Emirates.
By December 31, 2025, the SSi Mantra had an installed base of 168 systems across ten countries and had been used in 7,885 surgeries, including 390 cardiac and 121 pediatric procedures, plus more than 150 telesurgeries. The new approvals deepen the company’s access to underpenetrated and underserved markets, reinforcing its positioning as a cost-efficient alternative in surgical robotics and potentially accelerating adoption in emerging healthcare systems.
The most recent analyst rating on (SSII) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
Spark’s Take on SSII Stock
According to Spark, TipRanks’ AI Analyst, SSII is a Neutral.
The score is held back primarily by weak profitability and worsening cash burn despite rapid revenue growth and a strengthened balance sheet. Technicals are neutral-to-mixed with high volatility, while valuation is constrained by ongoing losses. Positive corporate events (approvals, adoption milestones, and fresh capital) provide meaningful upside support but are secondary to financial execution risk.
To see Spark’s full report on SSII stock, click here.
More about SS Innovations International
SS Innovations International, Inc. is a medical technology company that develops innovative surgical robotic systems aimed at making robotic surgery more affordable and accessible worldwide. Its portfolio includes the proprietary SSi Mantra surgical robotic platform and the SSi Mudra suite of surgical instruments, supporting a wide range of procedures including cardiac and pediatric surgery.
Headquartered in India but listed in the U.S., the company focuses on technologically advanced, user-friendly and cost-effective robotic solutions designed for both established and underserved healthcare markets. The SSi Mantra system features a modular multi-arm configuration, 3D 4K visualization, telesurgery capability, and a broad array of endo-surgical instruments validated across more than 100 procedure types.
Average Trading Volume: 94,884
Technical Sentiment Signal: Sell
Current Market Cap: $954.3M
For detailed information about SSII stock, go to TipRanks’ Stock Analysis page.